Israel Englander Biomea Fusion, Inc. Call Options Transaction History

Millennium Management LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	BUY	$4.23 - $10.1 $296,100 - $707,000	70,000 Added 140.0%	120,000 $1.21 Million
Q2 2024 Aug 14, 2024	BUY	$4.14 - $15.3 $124,199 - $459,000	30,000 Added 150.0%	50,000 $225,000
Q1 2024 May 15, 2024	SELL	$13.92 - $19.5 $417,600 - $585,000	-30,000 Reduced 60.0%	20,000 $299,000
Q4 2023 Feb 14, 2024	BUY	$8.37 - $19.8 $266,166 - $629,640	31,800 Added 174.73%	50,000 $726,000
Q2 2023 Aug 14, 2023	BUY	$21.66 - $41.8 $394,212 - $760,760	18,200 New	18,200 $399,000

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $171M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.